NCT06405581 The Impact of Frailty on Cardiopulmonary Resuscitation Adverse Outcomes in Patients Requiring Code Blue Activation
| NCT ID | NCT06405581 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Umraniye Education and Research Hospital |
| Condition | Cardiac Arrest |
| Study Type | OBSERVATIONAL |
| Enrollment | 2 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2 participants in total. It began in 2025-12-01 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study was to determine the independent association of frailty with cardiopulmonary resuscitation and predictive factors in patients triggering code blue response
Eligibility Criteria
Inclusion Criteria: * pediatric patients Exclusion Criteria: * pregnant patients
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06405581 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Cardiac Arrest. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06405581 currently recruiting?
Yes, NCT06405581 is actively recruiting participants. Contact the research team at zelihalara@yahoo.com for enrollment information.
Where is the NCT06405581 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye), Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT06405581 clinical trial?
NCT06405581 is sponsored by Umraniye Education and Research Hospital. The trial plans to enroll 2 participants.